Abstract: Serum thyroglobulin (Tg) is a major tumor marker for follow-up after treatment of patients with differentiated thyroid carcinoma (DTC). However, the accuracy of Tg measurement is interfered by thyroglobulin antibody (TgAb), limiting the predictive value of Tg. Therefore, the follow-up of DTCs with positive TgAb remains a clinical puzzlement. Some researchers have proposed that TgAb could also serve as a surrogate tumor marker for the monitoring of DTC, but it remains controversial over the relationship between TgAb and disease status or prognosis after treatment. This article reviewed the clinical significance of TgAb measurement in ¹³¹I therapy of DTC, in order to provide more evidence for clinical decision making in patients with positive TgAb.

Key words: Thyroglobulin antibody, Differentiated thyroid cancer, Radioactive iodine therapy, Clinical significance